Press releases
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
More ▼
Key statistics
On Monday, Akeso Inc (4RY:STU) closed at 4.06, 14.04% above the 52 week low of 3.56 set on Aug 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.12 |
---|---|
High | 4.12 |
Low | 4.06 |
Bid | 4.06 |
Offer | 4.24 |
Previous close | 4.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 13.55 |
Market cap | 30.65bn HKD |
EPS (TTM) | 2.61 HKD |
Data delayed at least 15 minutes, as of May 27 2024.
More ▼